FDA Bioterrorism Efforts Could Delay Rulemakings, Guidance Documents
This article was originally published in The Tan Sheet
Executive Summary
FDA's non-user fee activities, such as developing rules and guidances, may be pushed back due to the agency's bioterrorism response efforts, Office of Training & Communications Director Nancy Smith suggested Nov. 5